Emerging Biopharma

January 30th 2025

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung cancer who are PD-1 checkpoint inhibitor resistant.

January 27th 2025

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.

January 22nd 2025

The trial, developed in collaboration with Novotech, will specifically target dietary and alcohol-induced overindulgence.

January 14th 2025

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.